Rsv passive and active vaccines
AssigneeTrellis Bioscience, LLC
InventorsMilton J. Friedman, Lawrence M. Kauvar
Life of this patent
Estimating the term…
Abstract
Improvements to vaccines against RSV include G protein CCD portions complexed with mAb that block interaction with CX3C-R and modified forms of mAb to prolong serum half-life, as well as inhalable vaccines.
Claims23
1-15. (canceled)
An immunogen against respiratory syncytial virus (RSV) comprising a complex formed by an RSV G protein or peptidomimetic, wherein said RSV G protein includes a central conserved domain (CCD) with a monoclonal antibody or antigen binding fragment thereof that blocks interaction of the recombinant RSV G protein with host receptor CX3CR1.
A vaccine for prophylaxis or treatment of RSV formulated for inhalation comprising an immunogen against respiratory syncytial virus (RSV) comprising a complex formed by an RSV G protein or peptidomimetic, wherein said RSV G protein includes a central conserved domain (CCD) with a monoclonal antibody or antigen binding fragment thereof that blocks interaction of the recombinant RSV G protein with host receptor CX3CR1.
A method for prophylaxis or treatment of RSV infection in a subject, which method comprises effecting expression, in the cells of said subject, of an mAb or antigen-binding fragment thereof directed against the RSV G protein.
Dependencies are inferred from the claim text.